ER+, HER2− advanced breast cancer treated with taselisib and fulvestrant: genomic landscape and associated clinical outcomes

Taselisib is a potent β‐sparing phosphatidylinositol 3‐kinase (PI3K) inhibitor that, with endocrine therapy, improves outcomes in phosphatidylinositol‐4,5‐bisphosphate 3‐kinase catalytic subunit alpha (PIK3CA)‐mutated (PIK3CAmut) advanced breast cancer. To understand alterations associated with resp...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Jessica W., Jacot, William, Cortés, Javier, Krop, Ian E., Dent, Susan, Harbeck, Nadia, De Laurentiis, Michelino, Diéras, Véronique, Im, Young‐Hyuck, Stout, Thomas J., Schimmoller, Frauke, Savage, Heidi M., Hutchinson, Katherine E., Wilson, Timothy R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10552898/
https://www.ncbi.nlm.nih.gov/pubmed/36892268
http://dx.doi.org/10.1002/1878-0261.13416

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10552898/
https://www.ncbi.nlm.nih.gov/pubmed/36892268
http://dx.doi.org/10.1002/1878-0261.13416

Ejemplares similares